Quick Answer
BridgeBio Pharma, Inc. reported Earnings Per Share Diluted of $3.78 (loss) per share for the year ending 2025.
- BridgeBio Pharma, Inc. showed a decrease of -31.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.66 (loss) per share | Q3 2021: $1.06 (loss) per share | Q1 2022: $1.35 (loss) per share | Q2 2022: $0.07 (loss) per share | Q3 2022: $0.93 (loss) per share | Q1 2023: $0.92 (loss) per share | Q2 2023: $0.98 (loss) per share | Q3 2023: $1.08 (loss) per share | Q1 2024: $0.20 (loss) per share | Q2 2024: $0.39 (loss) per share | Q3 2024: $0.86 (loss) per share | Q1 2025: $0.88 (loss) per share | Q2 2025: $0.95 (loss) per share | Q3 2025: $0.95 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), BridgeBio Pharma, Inc.'s Earnings Per Share Diluted has grown by 0.5%.
- Historical annual values: Fiscal year 2025: $3.78 (loss) per share | Fiscal year 2024: $2.88 (loss) per share | Fiscal year 2023: $3.95 (loss) per share | Fiscal year 2022: $3.26 (loss) per share | Fiscal year 2021: $3.90 (loss) per share | Fiscal year 2020: $3.80 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: